Literature DB >> 24123812

Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.

Panagiotis Fotakis1, Ioanna Tiniakou, Andreas K Kateifides, Christina Gkolfinopoulou, Angeliki Chroni, Efstratios Stratikos, Vassilis I Zannis, Dimitris Kardassis.   

Abstract

We studied the significance of four hydrophobic residues within the 225-230 region of apoA-I on its structure and functions and their contribution to the biogenesis of HDL. Adenovirus-mediated gene transfer of an apoA-I[F225A/V227A/F229A/L230A] mutant in apoA-I⁻/⁻ mice decreased plasma cholesterol, HDL cholesterol, and apoA-I levels. When expressed in apoA-I⁻/⁻ × apoE⁻/⁻ mice, approximately 40% of the mutant apoA-I as well as mouse apoA-IV and apoB-48 appeared in the VLDL/IDL/LDL. In both mouse models, the apoA-I mutant generated small spherical particles of pre-β- and α4-HDL mobility. Coexpression of the apoA-I mutant and LCAT increased and shifted the-HDL cholesterol peak toward lower densities, created normal αHDL subpopulations, and generated spherical-HDL particles. Biophysical analyses suggested that the apoA-I[225-230] mutations led to a more compact folding that may limit the conformational flexibility of the protein. The mutations also reduced the ability of apoA-I to promote ABCA1-mediated cholesterol efflux and to activate LCAT to 31% and 66%, respectively, of the WT control. Overall, the apoA-I[225-230] mutations inhibited the biogenesis of-HDL and led to the accumulation of immature pre-β- and α4-HDL particles, a phenotype that could be corrected by administration of LCAT.

Entities:  

Keywords:  apolipoprotein A-I mutations; dyslipidemia; high density lipoprotein biogenesis; pre-β- and α-HDL particles

Mesh:

Substances:

Year:  2013        PMID: 24123812      PMCID: PMC3826677          DOI: 10.1194/jlr.M043489

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  20 in total

1.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system.

Authors:  Jinyong Luo; Zhong-Liang Deng; Xiaoji Luo; Ni Tang; Wen-Xin Song; Jin Chen; Katie A Sharff; Hue H Luu; Rex C Haydon; Kenneth W Kinzler; Bert Vogelstein; Tong-Chuan He
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

2.  Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3.

Authors:  Marta Biedzka-Sarek; Jari Metso; Andreas Kateifides; Taru Meri; T Sakari Jokiranta; Artur Muszyński; Joanna Radziejewska-Lebrecht; Vassilis Zannis; Mikael Skurnik; Matti Jauhiainen
Journal:  J Biol Chem       Date:  2011-09-06       Impact factor: 5.157

3.  Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells.

Authors:  Pascale M Ohnsorg; Lucia Rohrer; Damir Perisa; Andreas Kateifides; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis; Arnold von Eckardstein
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

4.  Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization.

Authors:  Xiaohu Mei; David Atkinson
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

5.  Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.

Authors:  Angeliki Chroni; Adelina Duka; Horng-Yuan Kan; Tong Liu; Vassilis I Zannis
Journal:  Biochemistry       Date:  2005-11-01       Impact factor: 3.162

6.  Crystallization of truncated human apolipoprotein A-I in a novel conformation.

Authors:  D W Borhani; J A Engler; C G Brouillette
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-09

7.  LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.

Authors:  Georgios Koukos; Angeliki Chroni; Adelina Duka; Dimitris Kardassis; Vassilis I Zannis
Journal:  Biochemistry       Date:  2007-08-21       Impact factor: 3.162

8.  Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.

Authors:  Angeliki Chroni; Horng-Yuan Kan; Adelina Shkodrani; Tong Liu; Vassilis I Zannis
Journal:  Biochemistry       Date:  2005-03-15       Impact factor: 3.162

9.  The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo.

Authors:  Angeliki Chroni; Georgios Koukos; Adelina Duka; Vassilis I Zannis
Journal:  Biochemistry       Date:  2007-04-21       Impact factor: 3.162

10.  Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.

Authors:  Georgios Koukos; Angeliki Chroni; Adelina Duka; Dimitris Kardassis; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

View more
  3 in total

1.  Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk.

Authors:  Christina Gkolfinopoulou; Faye Soukou; Ioannis Dafnis; Tahsin F Kellici; Despina Sanoudou; Thomas Mavromoustakos; Efstratios Stratikos; Angeliki Chroni
Journal:  Cell Mol Life Sci       Date:  2020-07-14       Impact factor: 9.261

2.  A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.

Authors:  Xiaodong Gu; Zhiping Wu; Ying Huang; Matthew A Wagner; Camelia Baleanu-Gogonea; Ryan A Mehl; Jennifer A Buffa; Anthony J DiDonato; Leah B Hazen; Paul L Fox; Valentin Gogonea; John S Parks; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-01-21       Impact factor: 5.157

Review 3.  Structural Insights into High Density Lipoprotein: Old Models and New Facts.

Authors:  Valentin Gogonea
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.